Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.56, $1.80 worse than the analyst estimate of $3.36. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $116.95 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Intuit (INTU) PT Lowered to $370 at Freedom Broker
• Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance